LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, David A. Eichenbaum, MD, FASRS, discusses study design and rationale for the phase 3 ARCHER II study.
The study is evaluating vonaprument (Annexon Biosciences) in patients with dry age-related macular degeneration and geographic atrophy.
“Vonaprument, which used to be called ANX007, has the potential to be the first geographic atrophy therapy that could preserve vision and allow patients worldwide to benefit from advancements in the treatment of dry macular degeneration, pending the